**Correction to**: *British Journal of Cancer* (2013) **109**, 60--67; doi:[10.1038/bjc.2013.226](/doifinder/10.1038/bjc.2013.226)

Since the advance online publication of this paper in May 2013, the authors realised that fresh calculations of the cohort of testicular cancer patients were required after omitting nine patients who received radiotherapy. This resulted in slightly incorrect numbers presented in the data displayed in [Tables 2](#tbl2){ref-type="table"}, [4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}, and in sections of the Results.

In order to present the results correctly moving forward, the data have now been corrected in the paper which appears in this issue and are represented in the Tables following (see below).

###### Characteristics of GCT survivors according to treatment group and of healthy subjects

                                                                                                               **Treatment groups**                                                                                                                                                                     
  ---------------------------------------------------------------- -------------------------------------- ------------------------------ ---------------------------------- -------------------------------------- ------------------------------------- ---------------------------------------------- ----------------------------------------------
  **Parameters**                                                    **Healthy subjects*****N*****=360)**   **Surgery (*****N*****=58)**   **Carboplatin (*****N*****=21)**   **Combination CT (*****N*****=176)**   **All survivors (*****N*****=255)**   ***P*****-value**[a](#t2-fn2){ref-type="fn"}   ***P*****-value**[b](#t2-fn3){ref-type="fn"}
  **Demographics mean±s.d., median (min--max)**                                                                                                                                                                                                                                                         
  Age at diagnosis (years)                                                           NA                     30.4±8.3 28.9 (20.0--61.9)      37.6±12.2 33.8 (24.8--50.6)           31.2±8.8 29.6 (14.2--54.2)            31.4±8.7 29.8 (14.2--61.9)                             ∼                                              ∼
  Age at blood analysis (years)                                           43.1±14.6 44.0 (18--70)          36.6±10.4 36.5 (20.1--69.5)      42.1±12.0 39.3 (26.8--57.4)          38.7±10.9 38.7 (18.2--63.4)            39.2±10.7 38.3 (18.2--69.5)                            NS                                             NS
  Interval between curative treatment and blood analysis (years)                     NA                        6.2±6.7 3.2 (0.1--2)           4.5±3.5 3.1 (0.7--13.2)              8.8±7.8 6.3 (0.6--30.2)                7.8±7.4 5.0 (0.1--30.2)                              ∼                                              ∼
  **Clinical characteristics: median (min--max)**                                                                                                                                                                                                                                                       
  Body weight (kg)                                                              85 (54--138)                       82 (60--138)                     83 (64--132)                         85 (60--126)                          84 (60--138)                                  0.005                                           0.01
  Height (m)                                                                 1.80 (1.57--2.06)                  1.85 (1.65--1.99)                1.83 (1.69--1.98)                    1.83 (1.65--2.01)                      1.83 (1.65--2.01)                               0.006                                         \<0.001
  Body mass index (kg m^−2^)                                                 25.8 (19.5--42.6)                  24.2 (16.8--38.5)                25.0 (20.5--35.8)                    25.6 (18.4--36.4)                      25.5 (16.8--38.5)                                 NS                                            0.01
  Waist circumference (cm)                                                      94 (74--130)                       92 (85--134)                     96 (81--137)                         96 (67--124)                          96 (67--137)                                 \<0.001                                         0.003
  Systolic blood pressure (mm Hg)[c](#t2-fn4){ref-type="fn"}                   130 (110--200)                     122 (95--185)                    130 (90--155)                        126 (90--200)                          125 (90--200)                                   NS                                           0.006
  Diastolic blood pressure (mm Hg)[c](#t2-fn4){ref-type="fn"}                   80 (62--110)                       80 (54--110)                     80 (65--90)                          80 (53--114)                          80 (53--114)                                    NS                                             NS
  Creatinine clearance (Cockroft formula; ml min^−1^)                                                             122 (84--205)                    120 (70--165)                        123 (56--217)                          122 (56--217)                                   ∼                                              ∼

Abbreviations: CT=chemotherapy; GCT=germ cell tumour; NA=not applicable; NS=not significant.

*P*-value for comparison between values of combination-CT survivors and healthy subjects (independent-samples Student\'s *t*-test or independent-samples Mann--Whitney where appropriate).

*P*-value for comparison between values of all survivors and healthy subjects (independent-samples Student\'s *t*-test or independent-samples Mann--Whitney where appropriate).

Systolic and diastolic blood pressure measurements for survivors treated with anti-hypertensive medication are excluded.

###### Prevalence of metabolic syndrome according to NCEP-ATPIII (upper part) and IDF criteria (lower part) in survivors and in healthy subjects

                                                                                                               **Treatment groups**                                                                                                                                                                                                                                                                          
  ------------------------------------------------- ---------------------------------------- -------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------
  **Parameters ℰ𝒩𝒯ℐ𝒯𝒴𝒮𝒯𝒜ℛ𝒯ℰ𝒩𝒯ℐ𝒯𝒴ℰ𝒩𝒟**                **Healthy subjects (*****N*****=360)**   **Surgery (*****N*****=57**[a](#t4-fn2){ref-type="fn"}   **Carboplatin (*****N*****=20**[a](#t4-fn2){ref-type="fn"}   **Combination CT (*****N*****=174**[a](#t4-fn2){ref-type="fn"}   **Survivors (*****N*****=251**[a](#t4-fn2){ref-type="fn"}   **Combination CT, OR (95% CI)**[b](#t4-fn3){ref-type="fn"}   **Survivors OR (95% CI)**[c](#t4-fn4){ref-type="fn"}
  **According to NCEP-ATP III**                                                                                                                                                                                                                                                                                                                                                                              
  Hypertension                                                     81 (22.5)                                         8 (14.0)                                                   4 (20.0)                                                      53 (31.0)                                                      66 (26.3)                                                 1.6 (1.0--2.3)                                            1.2 (0.8--1.8)
  Obesity                                                          70 (19.4)                                        10 (17.5)                                                   6 (30.0)                                                      51 (29.3)                                                      67 (26.7)                                                 1.7 (1.1--2.6)                                            1.5 (1.0--2.2)
  Insulin resistance                                                16 (4.4)                                         2 (3.5)                                                    1 (5.0)                                                        11 (6.3)                                                      14 (5.6)                                                  1.5 (0.7--3.2)                                            1.3 (0.6--2.7)
  Dyslipidemia[d](#t4-fn5){ref-type="fn"}                          36 (10.0)                                         7 (12.3)                                                   4 (20.0)                                                      35 (20.1)                                                      46 (18.3)                                                 2.3 (1.4--3.8)                                            2.0 (1.3--3.2)
  Hypertriglyceridemia[d](#t4-fn5){ref-type="fn"}                  84 (23.3)                                        13 (22.8)                                                   6 (30.0)                                                      61 (35.1)                                                      80 (31.9)                                                 1.8 (1.2--2.6)                                            1.5 (1.1--2.2)
  Metabolic syndrome                                                29 (8.1)                                         5 (8.8)                                                    2 (10.0)                                                      29 (16.7)                                                      36 (14.3)                                                 2.3 (1.3--4.0)                                            1.9 (1.1--3.2)
  **According to IDF**                                                                                                                                                                                                                                                                                                                                                                                       
  Hypertension                                                     170 (47.2)                                       21 (36.8)                                                   8 (40.0)                                                      83 (47.7)                                                     112 (44.6)                                                 1.0 (0.7--1.5)                                            0.9 (0.7--1.2)
  Obesity                                                          165 (45.8)                                       24 (42.1)                                                  13 (65.0)                                                      107 (61.5)                                                    144 (57.4)                                                 1.9 (1.3--2.7)                                            1.6 (1.1--2.2)
  Insulin resistance                                               57 (15.8)                                         6 (10.5)                                                   3 (15.0)                                                      34 (19.5)                                                      43 (17.1)                                                 1.3 (0.8--2.1)                                            1.1 (0.7--1.7)
  Dyslipidemia[d](#t4-fn5){ref-type="fn"}                          36 (10.0)                                         7 (12.3)                                                   4 (20.0)                                                      35 (20.1)                                                      46 (18.3)                                                 2.3 (1.4--3.8)                                            2.0 (1.3--3.2)
  Hypertriglyceridemia[d](#t4-fn5){ref-type="fn"}                  84 (23.3)                                        13 (22.8)                                                   6 (30.0)                                                      61 (35.1)                                                      80 (31.9)                                                 1.8 (1.2--2.6)                                            1.5 (1.1--2.2)
  Metabolic syndrome                                               59 (16.4)                                         9 (15.8)                                                   5 (25.0)                                                      52 (29.9)                                                      66 (26.3)                                                 2.2 (1.4--3.3)                                            1.8 (1.2--2.7)

Abbreviations: CT=chemotherapy; CI=confidence interval; GCT=germ cell tumour; IDF=International Diabetes Federation; OR=odds ratio; NCEP-ATPIII=National Cholesterol Education Program Adult Treatment Panel III 2001.

Four survivors diagnosed with diabetes mellitus before orchidectomy (*N*=1), single-dose carboplatin (*N*=1), or combination CT (*N*=2) are excluded in this table.

OR for risk stratification between healthy subjects and combination CTsurvivors.

OR for risk stratification between healthy subjects and all GCT survivors.

Prevalence of dyslipidemia and hypertriglyceridemia are similar according to NCEP-ATPIII and IDF criteria.

###### Metabolic syndrome prevalence and odds ratio\'s in four cross-sectional studies

  **Parameters**                                            **Nuver** ***et al*** (**2005**)                **Haugnes** ***et al*** (**2007**)                                                                                           **Wethal** ***et al*** (**2007**)               **this study**           
  -------------------------------------------------------- ---------------------------------- --------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------- ----------------- ----------------
  Number of survivors                                                     130                                              1135                                                                                                                         589                                    251                
  Mean age (years) (range)                                           38.5 (20--65)                                     42.5 (23--60)                                                                                                                42 (23--60)                           39.6 (18--70)           
  Mean follow-up time (years) (range)                                 7.5 (3--13)                                      11.2 (5--22)                                                                                                                11 (7.7--14.5)                        7.8 (0.1--30.0)          
  Healthy subjects (*N*)                                                   47                                              1150                                                                                                                         8835                                   360                
  Metabolic syndrome definition                                       NCEP-ATP III             Modified NCEP-ATP III ⩾ 2 criteria[a](#t5-fn2){ref-type="fn"}   Modified NCEP-ATP III ⩾3 criteria[a](#t5-fn2){ref-type="fn"}   Modified criteria ⩾3 criteria[a](#t5-fn2){ref-type="fn"}    NCEP-ATP III          IDF
  **Metabolic syndrome prevalence (%)**                                                                                                                                                                                                                                                                   
  All GCT survivors                                                    38 (29.2)                                        447 (39.4)                                                       92 (8.1)                                                    82 (13.9)                              36 (14.3)        66 (26.3)
  Combination CT                                                       22 (25.6)                                        191 (41.2)                                                       40 (8.6)                                                    38 (17.4)                              29 (16.7)        52 (29.9)
  Single-dose carboplatin                                                  ∼                                                 ∼                                                              ∼                                                            ∼                                  2 (10.0)          5 (25.0)
  Radiotherapy                                                             ∼                                            184 (42.0)                                                       37 (8.3)                                                    35 (15.2)                                  ∼                ∼
  Surgery only                                                         16 (34.0)                                         72 (33.0)                                                       15 (6.7)                                                     9 (6.4)                                5 (8.8)          9 (15.8)
  Healthy subjects                                                      4 (8.5)                                         584 (51.5)                                                      170 (14.8)                                                 Not mentioned                            29 (8.1)         59 (16.4)
  **OR (95% CI) adjustments[b](#t5-fn3){ref-type="fn"}**                                                                                                                                                                                                                                                  
  GCT survivors *vs* healthy subjects                               4.4 (1.5--13.2)                                   0.6 (0.5--0.7)                                                  0.5 (0.4--0.7)                                                     ∼                               1.9 (1.1--3.2)    1.8 (1.2--2.7)
  Combination CT *vs* healthy subjects                              3.7 (1.2--11.5)                                   0.7 (0.5--0.8)                                                  0.5 (0.4--0.8)                                               3.7 (1.5--9.1)                        2.3 (1.3--4.0)    2.2 (1.4--3.3)
  Combination chemotherapy *vs* surgery only                         0.6 (0.3--1.3)                                   1.5 (1.1--2.1)                                                  1.3 (0.7--2.4)                                               3.1 (1.4--6.6)                        2.1 (0.8--5.7)    2.3 (1.0--5.0)

Abbreviations: CI=confidence interval; CT=chemotherapy; GCT=germ cell tumour; IDF=International Diabetes Federation; OR=Odds ratio; NCEP-ATPIII=National Cholesterol Education Program Adult Treatment Panel III 2001.

Non-fasting blood samples.

Calculated from the raw data presented in the individual reports.
